A Phase 1/2 interventional study of Lenalidomide and Recombinant human erythropoietin in Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS), sponsored by Celgene Corporation. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-30.
Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing lenalidomide in Myelodysplastic Syndromes — none open to participants now, none under way, none of them phase 3. Lenalidomide · Myelodysplastic Syndromes.
Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, this one is the 17th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2005, is one of 7 in phase 1/2, and was the 19th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →None of the 44 studies testing lenalidomide in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 31 · Phase 3 3
First in 2002; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 32 across the 43 interventional studies. Of the 38 that completed or were terminated, 21 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene Corporation, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.
75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb: 4 open now, 9 under way, 5 of them phase 3. Of 63 finished, 20 (32%) have results posted.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 26th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2005, is one of 5 in phase 1/2, and was the 20th registered.
Bristol-Myers Squibb’s Myelodysplastic Syndromes studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 75 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess pharmacokinetic and pharmacodynamic characteristics of oral lenalidomide monotherapy administered to patients with Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented diagnosis of MDS that meets International Prognostic Scoring System (IPSS) criteria for Low- to Intermediate-1-risk disease.
•Must have a diagnosis of low- or intermediate- risk MDS without a del 5q chromosomal abnormality (patients taking 15 mg starting dose only).
Exclusion Criteria:
Any of the following lab abnormalities:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the Pharmacokinetic Phase received a single 10 mg oral dose of lenalidomide on Day -7. During the Monotherapy Phase participants received 10 mg oral lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure. During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 10 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment.
Drug: Lenalidomide · Drug: Recombinant human erythropoietin
Following the enrollment of the first 25 patients into the Monotherapy Phase, a second group of 15 patients with low- or intermediate-1-risk MDS not associated with a del 5q (non-del 5q) cytogenetic abnormality were enrolled to receive 15 mg of lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure. During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 15 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment.
Drug: Lenalidomide · Drug: Recombinant human erythropoietin
Lenalidomide 5-mg capsules for oral administration
Also known as: Revlimid
Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide
Area under the plasma concentration-time curve from Time 0 to 24 hours post-dose for lenalidomide after a single dose, calculated using the log-linear trapezoidal method.
Time frame: On Day -7 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours post-dose.
Monotherapy Phase: Area-under-the Concentration-time Curve (AUC0-5) for Lenalidomide
Area under the plasma concentration-time curve from Time 0 to 5 hours postdose for lenalidomide (its R- and S- enantiomers and the enantiomers combined) after multiple dosing for 14 days, calculated using the log-linear trapezoidal method.
Time frame: On Day 14 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, and 5 hours postdose.
PK Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)
The maximum observed plasma concentration (Cmax) of lenalidomide (its R- and S- enantiomers and the enantiomers combined) after a single dose on day -7.
Time frame: On Day -7 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose.
Monotherapy Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)
The Maximum observed plasma concentration (Cmax) of lenalidomide (its R- and S- enantiomers and the enantiomers combined) after multiple dosing for 14 days.
Time frame: On Day 14 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, and 5 hours postdose.
PK Phase: Terminal Half-life (t1/2)
The apparent terminal half-life is the time required for plasma concentration to decrease by 50% after pseudo-equilibrium of distribution has been reached, and calculated as the natural logarithm of 2 (0.693) / Apparent terminal rate constant (λz).
Time frame: On Day -7 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose.
PK Phase: Percent of Administered Lenalidomide Excreted Over 24 Hours After a Single, Oral Dose
Percent of the administered dose of lenalidomide excreted unchanged in urine over 24 hours postdose after a single dose on Day -7, calculated as: (amount excreted unchanged in urine over 24 hours postdose / Dose) \* 100. The dose was 10 mg for total lenalidomide and 5 mg for the enantiomers.
Time frame: On Day -7 at predose and over the intervals of 0-5, 5-8, 8-12, and 12-24 hours postdose.
Monotherapy Phase: Percent of Lenalidomide Excreted Over 5 Hours Post Day 14 Dose
Percent of the administered lenalidomide dose excreted unchanged in urine over 5 hours postdose after multiple dosing for 14 days, calculated as: (amount excreted unchanged in urine over the first 5 hours postdose / Dose) \* 100. The dose was 10 mg for total lenalidomide and 5 mg for the enantiomers.
Time frame: On Day 14, at predose and over the interval of 0-5 hours postdose.
Time to Grade 4 Neutropenia or Thrombocytopenia
Time to the first event of grade 4 neutropenia or thrombocytopenia, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0, was calculated as date of first event - date of first dose + 1.
Time frame: From the date of first dose until 30 days after the last dose (up to 1218 days)
Percentage of Participants With a Erythroid Response Across All Phases
Erythroid response was categorized as either a major response or a minor response. A major response was defined as red blood cell (RBC) transfusion independence during any consecutive 56-day period and an increase in hemoglobin of at least 1.5 g/dL. A minor response was defined as a ≥ 50% or ≥ 4 unit decrease in RBC transfusions from pretreatment requirements (the number of RBC transfusions required over an 8-week period before the start of study drug treatment).
Time frame: Assessed every 28 days until study discontinuation (up to 1218 days).
Percentage of Participants Overall With Erythroid Response by Baseline Erythropoietin Level
To evaluate the predictive value of pretreatment serum erythropoietin (EPO) concentration for erythroid response to lenalidomide, the percentage of erythroid responders versus non-responders were stratified by Baseline EPO levels (≤ 500 mIU/mL versus \> 500 mIU/mL). Response includes participants with either a major or minor response.
Time frame: Assessed every 28 days until study discontinuation (up to 1218 days)
Change From Baseline in Bone Marrow Cellularity and Correlation With Grade 4 Myelosuppression
Bone marrow cellularity is the volume ratio of hematopoietic stem cells and adipocytes (fat cells). Due to the small number of bone marrow samples, this analysis was not performed.
Time frame: Baseline and Week 16
Marrow-infiltrating Lymphocyte (MIL) Number and Cytolytic Activity
Due to the low number of bone marrow samples collected this analysis was not performed.
Time frame: Pre-Study and Week 16
A total of 40 participants were enrolled at 1 site in this study, with 12 participants enrolled in the Pharmacokinetic (PK) Phase of the study, 39 participants enrolled in the Monotherapy Phase of the study, and 23 participants enrolled in the Combined Treatment Phase of the study.
| Milestone | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q |
|---|---|---|---|
| Started | 9 | 0 | 3 |
| Completed | 8 | 0 | 3 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Milestone | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q |
|---|---|---|---|
| Started | 17 | 15 | 7 |
| Safety population | 17 | 15 | 7 |
| Pharmacokinetic population | 17 | 0 | 7 |
| Completed | 0 | 0 | 0 |
| Not completed | 17 | 15 | 7 |
| Withdrew: Adverse event | 3 | 2 | 0 |
| Withdrew: Lack of therapeutic effect | 9 | 6 | 4 |
| Withdrew: Withdrawal by subject | 1 | 3 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Other | 3 | 4 | 2 |
| Milestone | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q |
|---|---|---|---|
| Started | 9 | 10 | 4 |
| Completed | 0 | 0 | 0 |
| Not completed | 9 | 10 | 4 |
| Withdrew: Lack of therapeutic effect | 8 | 6 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 1 |
Area under the plasma concentration-time curve from Time 0 to 24 hours post-dose for lenalidomide after a single dose, calculated using the log-linear trapezoidal method.
| ng*h/mL | 10 mg Lenalidomide |
|---|---|
| PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide | 817 ± 30.5 |
The maximum observed plasma concentration (Cmax) of lenalidomide (its R- and S- enantiomers and the enantiomers combined) after a single dose on day -7.
| ng/mL | 10 mg Lenalidomide |
|---|---|
| Total Lenalidomide | 179 ± 33.6 |
| S-Lenalidomide | 101 ± 34.9 |
| R-Lenalidomide | 78.3 ± 32.7 |
The Maximum observed plasma concentration (Cmax) of lenalidomide (its R- and S- enantiomers and the enantiomers combined) after multiple dosing for 14 days.
| ng/mL | 10 mg Lenalidomide |
|---|---|
| Total Lenalidomide | 185 ± 38.7 |
| S-Lenalidomide | 104 ± 39 |
| R-Lenalidomide | 80.7 ± 38.8 |
The apparent terminal half-life is the time required for plasma concentration to decrease by 50% after pseudo-equilibrium of distribution has been reached, and calculated as the natural logarithm of 2 (0.693) / Apparent terminal rate constant (λz).
| hours | 10 mg Lenalidomide |
|---|---|
| Total Lenalidomide | 3.72 ± 19.5 |
| S-Lenalidomide | 4.14 ± 29.0 |
| R-Lenalidomide | 3.58 ± 21.4 |
Percent of the administered dose of lenalidomide excreted unchanged in urine over 24 hours postdose after a single dose on Day -7, calculated as: (amount excreted unchanged in urine over 24 hours postdose / Dose) \* 100. The dose was 10 mg for total lenalidomide and 5 mg for the enantiomers.
| percent of administered dose | 10 mg Lenalidomide |
|---|---|
| Total Lenalidomide | 65.1 ± 13.5 |
| S-Lenalidomide | 67.9 ± 13.9 |
| R-Lenalidomide | 62.2 ± 14.0 |
Percent of the administered lenalidomide dose excreted unchanged in urine over 5 hours postdose after multiple dosing for 14 days, calculated as: (amount excreted unchanged in urine over the first 5 hours postdose / Dose) \* 100. The dose was 10 mg for total lenalidomide and 5 mg for the enantiomers.
| percent of administered dose | 10 mg Lenalidomide |
|---|---|
| Total Lenalidomide | 34.0 ± 60.3 |
| S-Lenalidomide | 35.4 ± 59.0 |
| R-Lenalidomide | 32.5 ± 62.0 |
Time to the first event of grade 4 neutropenia or thrombocytopenia, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0, was calculated as date of first event - date of first dose + 1.
| days | Non-del 5q | Del 5q |
|---|---|---|
| Grade 4 Neutropenia | 69.0 (11 to 168) | 28.0 (17 to 36) |
| Grade 4 Thrombocytopenia | 53.0 (22 to 141) | 29.0 (22 to 36) |
Erythroid response was categorized as either a major response or a minor response. A major response was defined as red blood cell (RBC) transfusion independence during any consecutive 56-day period and an increase in hemoglobin of at least 1.5 g/dL. A minor response was defined as a ≥ 50% or ≥ 4 unit decrease in RBC transfusions from pretreatment requirements (the number of RBC transfusions required over an 8-week period before the start of study drug treatment).
| percentage of participants | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q |
|---|---|---|---|
| Major response | 17.6 | 40.0 | 85.7 |
| Minor response | 5.9 | 0 | 0 |
To evaluate the predictive value of pretreatment serum erythropoietin (EPO) concentration for erythroid response to lenalidomide, the percentage of erythroid responders versus non-responders were stratified by Baseline EPO levels (≤ 500 mIU/mL versus \> 500 mIU/mL). Response includes participants with either a major or minor response.
| percentage of participants | Responders | Non-responders | Overall |
|---|---|---|---|
| Baseline EPO ≤ 500 mIU/mL | 62.5 | 47.8 | 53.8 |
| Baseline EPO > 500 mIU/mL | 37.5 | 39.1 | 38.5 |
Bone marrow cellularity is the volume ratio of hematopoietic stem cells and adipocytes (fat cells). Due to the small number of bone marrow samples, this analysis was not performed.
No measurements were reported for this outcome.
Area under the plasma concentration-time curve from Time 0 to 5 hours postdose for lenalidomide (its R- and S- enantiomers and the enantiomers combined) after multiple dosing for 14 days, calculated using the log-linear trapezoidal method.
| ng*h/mL | 10 mg Lenalidomide |
|---|---|
| Total Lenalidomide | 563 ± 32.5 |
| S-Lenalidomide | 315 ± 34.2 |
| R-Lenalidomide | 248 ± 30.6 |
Due to the low number of bone marrow samples collected this analysis was not performed.
No measurements were reported for this outcome.
Collected over The safety analyses were conducted on data collected from the time of first dose of study drug to 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 mg Lenalidomide | — | 10/24 (41.7%) | 24/24 (100%) |
| 15 mg Lenalidomide | — | 5/15 (33.3%) | 15/15 (100%) |
| Event | 10 mg Lenalidomide | 15 mg Lenalidomide |
|---|---|---|
| AstheniaGeneral disorders | 0/24 | 1/15 |
| Pneumonia NOSInfections and infestations | 1/24 | 1/15 |
| Cardiac failure congestiveCardiac disorders | 1/24 | 1/15 |
| Deep vein thrombosisVascular disorders | 0/24 | 1/15 |
| Urinary retentionRenal and urinary disorders | 0/24 | 1/15 |
| Disease progression NOSGeneral disorders | 1/24 | 0/15 |
| FatigueGeneral disorders | 1/24 | 0/15 |
| ParotitisInfections and infestations | 1/24 | 0/15 |
| Sepsis NOSInfections and infestations | 1/24 | 0/15 |
| Myocardial infarctionCardiac disorders | 1/24 | 0/15 |
| Event | 10 mg Lenalidomide | 15 mg Lenalidomide |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 22/24 | 14/15 |
| Leukopenia NOSBlood and lymphatic system disorders | 21/24 | 12/15 |
| ThrombocytopeniaBlood and lymphatic system disorders | 21/24 | 11/15 |
| Diarrhoea NOSGastrointestinal disorders | 10/24 | 11/15 |
| Anaemia NOSBlood and lymphatic system disorders | 17/24 | 9/15 |
| PruritusSkin and subcutaneous tissue disorders | 9/24 | 7/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/24 | 7/15 |
| ConstipationGastrointestinal disorders | 5/24 | 5/15 |
| Dyspnoea NOSRespiratory, thoracic and mediastinal disorders | 2/24 | 5/15 |
| Rash NOSSkin and subcutaneous tissue disorders | 7/24 | 2/15 |
| Age Continuous(years) | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q | Total |
|---|---|---|---|---|
| Mean | 67.8 ± 10.96 | 73.4 ± 6.51 | 72.6 ± 7.39 | 70.8 ± 9.07 |
| Sex: Female, Male(Participants) | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q | Total |
|---|---|---|---|---|
| Female | 3 | 4 | 4 | 11 |
| Male | 14 | 11 | 3 | 28 |
| Race/Ethnicity, Customized(participants) | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q | Total |
|---|---|---|---|---|
| White | 17 | 13 | 7 | 37 |
| Hispanic | 1 | 1 | 0 | 2 |
| Other | 1 | 1 | 0 | 2 |
| Duration of MDS(years) | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q | Total |
|---|---|---|---|---|
| Mean | 2.8 ± 2.28 | 2.6 ± 2.22 | 4.2 ± 4.74 | 3.0 ± 2.81 |
| International Prognostic Scoring System (IPSS) Score(participants) | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q | Total |
|---|---|---|---|---|
| Low risk (0) | 8 | 8 | 2 | 18 |
| Intermediate-1 (0.5-1.0) | 9 | 7 | 5 | 21 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q | Total |
|---|---|---|---|---|
| 0 | 2 | 4 | 1 | 7 |
| 1 | 14 | 11 | 6 | 31 |
| 2 | 1 | 0 | 0 | 1 |
| French-American-British (FAB) classification of MDS(participants) | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q | Total |
|---|---|---|---|---|
| Refractory anemia (RA) | 6 | 7 | 2 | 15 |
| Refractory anemia with ringed sideroblasts (RARS) | 5 | 6 | 0 | 11 |
| Refractory anemia with excess blasts (RAEB) | 3 | 1 | 4 | 8 |
| Refractory anemia with excess blasts -1 (RAEB-1) | 0 | 1 | 0 | 1 |
| Other | 3 | 0 | 1 | 4 |
| Serum erythropoietin level(participants) | 10 mg Non-del 5q | 15 mg Non-del 5q | 10 mg Del 5q | Total |
|---|---|---|---|---|
| < 500 mIU/mL | 9 | 4 | 2 | 15 |
| ≥ 500 mIU/mL | 7 | 2 | 5 | 14 |
| Missing | 1 | 9 | 0 | 10 |
The record gives a start of Jan 2005, a primary completion of Apr 2006 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 7 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide